A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
← catalyst calendarNCT07000357 · readout in 1,164 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
15,100estimated
Sites
1,365
Countries
Argentina, Brazil, Bulgaria +33
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-04 | actual | When the study began enrolling |
| Primary completion | 2029-10-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiovascular Disease
Interventions
- Drug: AZD0780
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to first event of any component of MACE-PLUS
measured Up to approximately 54 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed